Early Access — free while we kick the tires
EdgarHawk

BVF PARTNERS L P/IL

Director

Director 10% Owner

Latest: Director selling · March 2026

6 filings analyzed · 4 companies · Latest 2026-04-02

Companies

Company Buys Sells Direction
MoonLake Immunotherapeutics MLTX 0 6 Net selling
Kymera Therapeutics, Inc. KYMR 3 0 Net buying
XOMA Royalty Corp XOMA 0 6 Net selling
Third Harmonic Bio, Inc. THRD 0 3 Net selling

Activity

April 2026
high
Sell
3,750,000 shares
$62,962,500
Significance 7/10

BVF Partners L P/IL sells 3,750,000 shares (78.3% of holdings) at $16.79; stock down 72% from 52-wk high, company unprofitable.

BVF Partners L P/IL filed a Form 4 reporting 3 separate sales totaling 3,750,000 shares for $62,962,500.00 at $16.79 per share on 2026-03-31, reducing its position from 4,789,238 to 1,039,238 shares (a -78.3% reduction). The current price of $17.36 is -72.0% from the 52-week high of $61.99, indicating substantial deterioration in valuation since the insider's entry. The underlying company reported a full-year net income of $-69,729,000.00, confirming unprofitability in its most recent fiscal year. At this same ticker, the insider's prior 3 sales (2024-10-04) all underperformed with a 0 of 3 well-timed rate at the 90-day mark, though this current filing's outcome remains to be observed. The magnitude of the share reduction and the stock's proximity to multi-year lows warrant close monitoring of subsequent company filings and guidance to assess whether this transaction reflects a reassessment of fundamentals.

July 2025
high
Buy
317,167 shares
$13,955,348
Significance 8/10

BVF Partners L P/IL acquired 317,167 shares at $44.00 for $13,955,348.00, expanding stakes 875.1%.

BVF Partners L P/IL, a director, executed 3 separate purchases totaling 317,167 shares for $13,955,348.00 at a blended average price of $44.00 on 2025-06-30, increasing holdings from 36,245 to 353,412 shares—a 875.1% increase. The transaction represents a substantial capital commitment at a price point (30-day change: +49.9%, 90-day change: +68.6%) within striking distance of the 52-week high of $52.40. The insider's cross-ticker track record shows 5 prior buys with a 100.00% 90-day win rate and average 90-day return of +15.6%, though Kymera presents a material headwind: the company posted $-65,581,000.00 net income against $22,100,000.00 quarterly revenue and negative annual growth of -40.1%, indicating structural challenges that diverge from the strong historical performance pattern. The scale of capital deployed and the near-peak entry point warrant close monitoring of both the fundamental trajectory and management's strategic rationale.

May 2025
2025-05-20 XOMA Royalty Corp XOMA
high
Sell
392,723 shares
$10,642,793
Significance 6/10

10% owner BVF Partners sells 392,723 shares at $27.10 for $10.6M, reducing stake by 23.7% while stock trails 52-week high by 21.5%

BVF Partners, a 10% shareholder in XOMA Royalty Corp, executed 2 separate sales totaling 392,723 shares (392.7K shares) for $10,642,793.30 ($10.6M) at $27.10 per share on 2025-05-16, reducing holdings from 1,660,268 shares to 1,267,545 shares (a 23.7% reduction). At the filing date, XOMA's stock was trading at $26.60, down 21.5% from its 52-week high of $33.88 but up 25.6% over the prior 30 days. Critically, across BVF Partners' prior 4 sales at XOMA specifically, all were well-timed: each achieved 90-day negative returns, with the most recent January 2025 sales posting -7.2% 90-day performance—meaning the stock fell after those sales, as happened in this case. This pattern of well-timed exits at the ticker level, combined with a 76.92% well-timed rate across the insider's 13 prior cross-ticker sales, suggests experienced capital allocation decisions. The fundamental context shows XOMA swung from unprofitability in the full prior fiscal year to $2.4M net income in the latest quarter, alongside massive 498.7% annual revenue growth, but these improvements have not yet arrested a general retreat from the 52-week high.

January 2025
2025-01-28 XOMA Royalty Corp XOMA
high
Sell
650,717 shares
$16,983,714
Significance 6/10

10% owner BVF PARTNERS L P/IL exits 650.7K shares (100% of stake) for $16,983,713.70 at $26.10

BVF PARTNERS L P/IL completed the total liquidation of its 650.7K share position in XOMA via 4 separate sales on 2025-01-24, raising $16,983,713.70 at $26.10 per share. The company is unprofitable with quarterly revenue of $7,197,000.00 and negative net income of $-17,243,000.00, alongside annual revenue contraction of -21.1%. The insider's cross-ticker track record shows strong buy timing (11 prior buys with 100% 90-day win rate averaging +45.0% return) but less reliable sell execution (9 prior sells with 66.67% well-timed rate and flat average 90-day return of -1.2%), meaning this exit follows a pattern of inconsistent timing on sale decisions. The complete exit removes a significant 10% stakeholder from the cap table and eliminates any ongoing downside protection for remaining shareholders.

October 2024
high
Sell
1,000,000 shares
$14,300,000
Significance 7/10

BVF PARTNERS sells 1,000,000 THRD shares (85.0% of pre-transaction holdings) for $14.3M at $14.30 on 2024-10-29

BVF PARTNERS L P/IL executed 3 separate sales totaling 1,000,000 shares (1.00M shares) for $14,300,000.00 on 2024-10-29, eliminating 85.0% of its pre-transaction holdings of 1,176,692 shares (1.18M shares). The sale occurred at a blended average price of $14.30, which represents a 3.7% premium to the current price of $13.79 and sits -11.3% from the 52-week high of $15.54. Notably, the insider's cross-ticker sell track record shows an average 90-day return of +0.4% after prior sales, with a 0.00% well-timed rate, indicating historically poorly-timed exits. The target company (THRD) is unprofitable with full-year net income of $-10,707,000.00 and a P/E ratio of 17.68 applied to negative earnings.

high
Sell
2,000,000 shares
$100,003,200
Significance 7/10

Director BVF Partners sold 2,000,000 shares ($100.0M) at $50.00; retains 1,287,768 shares post-sale

BVF Partners L P/IL, a director, executed 3 separate sales totaling 2,000,000 shares for $100,003,200.00 at $50.00 on 2024-10-04, reducing holdings by -60.8% from 3,287,768 to 1,287,768 shares. The company is unprofitable (net income $-24,267,012.00 over its most recent full fiscal year), and this substantial single-day liquidation of majority holdings occurs while the stock is -21.9% from its 52-week high of $63.86. The insider's cross-ticker track record shows a poor sell-timing pattern with 0.00% 90d well-timed rate across prior sales, indicating prior dispositions were followed by continued stock appreciation rather than declines. The magnitude and composition of this sale—a near-total reduction in director-level equity stake during a period of operating losses and elevated valuation distance from recent peaks—merit investor attention to the dynamics that prompted such a substantial equity reduction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access